Vaccine-like immune treatment to prevent lung infections in seniors
Part of Immune system & allergy clinical trials.
This Phase 2 study tests a site-specific immune “booster” in people age 65 and older to help improve natural immunity and reduce respiratory (lung/airway) infections. You may be eligible if you can consent, are in an eligible living situation, and are not currently using certain immune-suppressing medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 65 or older
- You live in the community or in a participating long-term care, independent-living, or assisted-living facility
- You can sign informed consent yourself (no legal guardian consent listed)
- You’re not expected to die within the next 3 months
- You are not using immune-suppressing medicines like certain biologics or other strong immune blockers
- You haven’t taken systemic antibiotics or antivirals recently (within 30 days), and you aren’t currently being treated for an infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called OM 85 that may help prevent respiratory infections (like pneumonia) in older adults living in nursing homes. If you are 75 or older and have had infections recently, this trial could be a way to stay healthier.
This trial tests whether an immune defense protein can help reduce upper respiratory infections (like colds) in people aged 60 and older. It may be a good fit if you get colds or flu-like symptoms several times each season.
This trial studies how well your immune system responds to a vaccine in people who are younger adults or, especially, older adults and those with frailty. Your participation may help researchers understand why vaccine responses can differ with age.
This trial tests a new vaccine designed to help protect older adults from infections that can affect breathing. You might be able to join if you're in generally good health and meet the other requirements listed below.
This study looks at how well a COVID-19 booster works in adults who need long-term medicines that lower immune response. It aims to see whether immunosuppressed people benefit from booster vaccination safely.
This trial tests a new drug called QLS2312, given as an injection, to see if it is safe and how the body handles it. It is an early study in healthy volunteers that helps decide if the drug can be studied in people with certain conditions.
Hear when a new Immune Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.